Navigation Links
Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients

CHICAGO, DARMSTADT, Germany, June 5, 2007 – This year’s American Society of Clinical Oncology (ASCO) meeting in Chicago sees a wealth of promising new data presented regarding Merck KGaA’s targeted cancer therapy Erbitux® (cetuximab), further demonstrating the consistent efficacy and versatility of this agent in both first-line and subsequent treatment of metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN).

Two new studies presented at the meeting validate the role of Erbitux as an effective first-line treatment in mCRC patients, when used in conjunction with two different types of chemotherapy treatment. The CRYSTAL(a) trial, a phase III study of Erbitux plus FOLFIRI (irinotecan-based therapy) compared with FOLFIRI alone, met the primary endpoint of significantly increasing median duration of progression-free survival in patients with previously untreated mCRC. This randomized, controlled international trial studied over 1,000 patients and demonstrated a statistically significant increase of progression-free survival in the Erbitux/FOLFIRI group (8.9 months) compared with the FOLFIRI group (8 months) (p=0.0479). However, this is a point estimate; more importantly, the overall curve showed a 15% reduction in the risk of metastatic colorectal cancer growing or spreading. The study also achieved its secondary endpoint of significantly increasing response rate (tumor shrinkage by 50% or more) (47% in the Erbitux plus FOLFIRI group compared to 39% in the FOLFIRI alone group). Furthermore, in a subgroup analysis, patients who had liver metastases only had the highest PFS (11.4 months with Erbitux vs. 9.2 months in the control arm) and a 36% reduction in the risk of metastatic colorectal cancer growing or spreading. The number of complete resections of the metastases in the subgroup who had liver metastases only was more than double with Erbitux plus FOLFIRI vs. control arm (9.8% versus 4.5%). The nu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:6/30/2015)... SHANGHAI , June 30, 2015 Today, ... officially signed an agreement with Chengdu Tianyi Exhibition Co., ... West , which is to be held concurrently with ... member to UBM,s healthcare exhibition family, following MEDTEC China ... equipment exhibition market in west China. It,s also another ...
(Date:6/30/2015)... -- July 4 th is this weekend, a time we ... people behind it. To help honor our current nation,s heroes, ... Medical Card, a leading provider of free pharmacy ... independence for our disabled military veterans, police, firemen, and EMS ... prescriptions. "Due to USA ...
(Date:6/30/2015)... RESEARCH TRIANGLE PARK, N.C. , June 30, 2015 ... solutions and services to the life sciences industry, has ... first direct to patient shipment of clinical drug product ... in South Korea to continue ... Middle East Respiratory System (MERS). The emergency ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3
... According to an overview of industry data released ... , in Fiscal Year 2011, pharmaceutical companies continued a ... delay the introduction of lower-cost prescription drug alternatives for ... that drug companies entered into 28 potential pay-for-delay ...
... ABAXIS, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... the second fiscal quarter ended September 30, 2011. ... $40.0 million, up 13% over last year,s comparable quarter. ... over last year,s comparable quarter. Veterinary market sales ...
Cached Medicine Technology:FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 2FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 2Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 4Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 5Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 6Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 7Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 8Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 9
(Date:6/30/2015)... ... June 30, 2015 , ... The Citizens ... Danny Davis (D-IL) for writing to the Department of Health and Human Services ... behavioral healthcare system, Universal Health Services (UHS).[1] CCHR is expanding its seven-year review ...
(Date:6/30/2015)... ... June 30, 2015 , ... India Network Foundation today announced ... its visitor health insurance plans that provides coverage for visitors to the United States. ... enable visitors to obtain services from most experienced health care professional close to their ...
(Date:6/30/2015)... ... 2015 , ... The League for Innovation in the Community ... Predictive Analytics Reporting (PAR) Framework, and Susan Rundell Singer, Director of the Division ... at the 2015 STEMtech conference in Phoenix, Arizona, November 1-4. , Opening ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... advanced protection at less thickness than any other padding in football. , Developed ... protection and shock absorption, Gameday Armour is engineered with D3O protective polymer. This ...
(Date:6/30/2015)... ... June 30, 2015 , ... Amerec, a division of TyloHelo Inc, is ... AEC Daily is now approved by the Interior Design Continuing Education Council for 1 ... an overview and explanation of what sauna, steam, and far-infrared saunas are, where they ...
Breaking Medicine News(10 mins):Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5Health News:India Network Announces Accessibility of First Health PPO Nationwide Network for Visitor Health Insurance Plan Participants Effective July 1, 2015 2Health News:India Network Announces Accessibility of First Health PPO Nationwide Network for Visitor Health Insurance Plan Participants Effective July 1, 2015 3Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2Health News:Amerec’s Steam and Sauna Continuing Education Course Now Approved for Interior Design Credit 2
... memory could offer an early warning system for Alzheimer ... Rush University Medical Center. The researchers have found// that ... in the brain related to Alzheimer's disease. Their findings ... ,The researchers looked at the association between ...
... found out that a protein called NMNAT can delay the ... level. The researchers from Baylor College of// Medicine in a ... online today said that NMNAT protects against nerve cell degeneration ... the question if a drug might be developed that could ...
... a International Labor Organization (ILO) report issued on Dec 1 ... to work partially or fully due to// HIV and million ... added that the virus had a crippling effect on the ... virus has among children has threatened the future working generations ...
... wines that belong to the vineyards of France and Italy are ... effects of fatty meals on the heart can be offset by ... has shown. Wines from these regions contain high levels of a ... have also proved the heart healthy benefits of a daily glass ...
... at the time of vaccination may reduce the effectiveness of ... is vaccinated, the goal is to produce as many antibodies ... EurekAlert. ,To do this, white blood cells (B ... defend the body against infections spring into action to produce ...
... and colleagues at four other medical centers have launched ... may contribute to early atherosclerosis. ,“If we can ... who have a genetic predisposition to develop atherosclerosis, we ... stroke sooner and more aggressively,” said David Herrington, M.D., ...
Cached Medicine News:Health News:Memory Complaints Are Associated With Alzheimer's Disease 2Health News:Memory Complaints Are Associated With Alzheimer's Disease 3Health News:NMNAT Protein Protects Against Nerve Cell Degeneration 2Health News:ILO Reports On The Crippling Effects Of HIV On The Workforce 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: